A Phase II Trial of Selinexor (KPT-330) for Metastatic Triple-Negative Breast Cancer.

ABSTRACT:

Lessons learned

Single-agent selinexor has limited activity in heavily pretreated patients with metastatic triple-negative breast cancer.Selinexor 60 mg by mouth twice weekly was generally well tolerated with a side-effect profile consistent with previous clinical trials.Future studies of selinexor in this population should focus on combination approaches and a biomarker-driven strategy to identify patients most likely to benefit.

Background

This phase II trial evaluated the safety, pharmacodynamics, and efficacy of selinexor (KPT-330), an oral selective inhibitor of nuclear export (SINE) in patients with advanced triple-negative breast cancer (TNBC).

Methods

This phase II trial was designed to enroll 30 patients with metastatic TNBC. Selinexor was given at 60 mg oral

SUBMITTER: Shafique M 

PROVIDER: S-EPMC6656474 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature